Kappa light chain myeloma: A case report
Open Access
- 7 March 2021
- journal article
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 3 (Supplement), 69-70
- https://doi.org/10.46310/tjim.876429
Abstract
Light chain myeloma nephropathy is the most common form of renal involvement in plasma cell dyscrasias. It usually causes tubulointerstitial renal damage. About one in five people with multiple myeloma produce only light chains. We report a case of lambda light chain deposition disease in a 61-year-old female who presented with acute renal failure . She is currently in partial remission following treatment with bortezomib, cyclophosphamide, and steroids.We present a case with rare kappa light chain myeloma with light chain deposition in renal tubules.Keywords
This publication has 8 references indexed in Scilit:
- Monitoring of light chain myeloma - time for a changeBritish Journal of Haematology, 2017
- Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patientsNephrology Dialysis Transplantation, 2015
- Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple MyelomaPLOS ONE, 2015
- Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term studyWorld Journal of Surgical Oncology, 2014
- Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysisNephrology Dialysis Transplantation, 2012
- Evaluation of Blood Purification and Bortezomib Plus Dexamethasone Therapy for the Treatment of Acute Renal Failure Due to Myeloma Cast NephropathyTherapeutic Apheresis and Dialysis, 2010
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patientsEuropean Journal of Haematology, 1994